Journal Spotlight
Tumor Genomic Profile and Risk for Arterial Thromboembolism in Patients With Solid Cancer
Matthew Stenger
In a single-institution study reported in JACC: CardioOncology, Stephanie Feldman, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that somatic KRAS and STK11 alterations were associated with increased risk of arterial thromboembolism in patients with solid tumors, irrespectiv...
Survival in Patients With Neuroblastoma on Reduced Therapy as a Result of Change in COG Risk Stratification
Matthew Stenger
In an analysis recently reported in the Journal of Clinical Oncology,1 Bender et al found that “excellent” survival outcomes were achieved in patients receiving reduced treatment for neuroblastoma as a result of reassignment to intermediate risk from high risk based on a change in the minimum age fo...
American College of Surgeons Evaluates the Impact of COVID-19 Pandemic on National Cancer Database Reporting
The ASCO Post Staff
New research from the American College of Surgeons (ACS) outlines significant ways that the COVID-19 pandemic destabilized usual patterns of cancer care, as reported in the National Cancer Database (NCDB). The NCDB is one of the largest cancer registries in the world and is used by thousands of hosp...
Radiation Oncology Workforce Expected to Remain Stable Through 2030
The ASCO Post Staff
A new analysis of the U.S. radiation oncology workforce projects a relative balance between the supply of radiation oncologists and the demand for radiation therapy services through 2030.1 The report was produced by Health Management Associates (HMA), a consulting firm commissioned by the American S...
Circulating Tumor DNA Identified Prior to and During Treatment Is Associated With Poorer Outcomes in Primary CNS Lymphoma
Matthew Stenger
In a collaborative study from the University of Freiburg and Stanford University reported in the Journal of Clinical Oncology, Jurik A. Mutter, BSc, of the Faculty of Medicine, University of Freiburg, and colleagues found that circulating tumor DNA (ctDNA) identified prior to and during treatment ...
Detection of Early Emphysema During Lung Cancer Screening: Opportunities to Optimize Health
Matthew Stenger
In an article in Annals of the American Thoracic Society, James L. Mulshine, MD, of the Center for Healthy Aging, Department of Medicine, Rush University, and colleagues maintained that the high frequency of emphysema newly identified during low-dose computed tomography (CT) lung cancer screening ...
Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma
Matthew Stenger
As reported in The New England Journal of Medicine by Paula Rodriguez-Otero, MD, PhD, of Clínica Universidad de Navarra, Pamplona, Spain, and colleagues, an interim analysis of the phase III KarMMa-3 trial has shown superior progression-free survival with the B-cell maturation antigen–directed chime...
Yale Study Indicates Older Patients Are Excluded From Progress Against Lung Cancer
The ASCO Post Staff
The widespread use of immune checkpoint inhibitors has led to significant benefits in younger patients with advanced lung cancer; however, older patients have not experienced similar survival benefits, according to research from Yale Cancer Center. The study was published in JAMA Oncology.1 “Ther...
DESTINY-Breast03: T-DXd Improves Overall Survival vs T-DM1 in Previously Treated HER2-Positive Metastatic Breast Cancer
Matthew Stenger
As reported in The Lancet by Sara A. Hurvitz, MD, of the David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, and colleagues, updated results of the phase III DESTINY-Breast03 trial showed significantly improved overall survival with fam-trastu...
Sotorasib Improves Progression-Free Survival vs Docetaxel in Previously Treated Advanced NSCLC With KRAS G12C Mutation
Matthew Stenger
As reported in The Lancet by Adrianus Johannes de Langen, MD, PhD, of the Netherlands Cancer Institute, Amsterdam, and colleagues, the phase III CodeBreaK200 trial has shown a small but significant improvement in progression-free survival with sotorasib vs docetaxel in previously treated advanced n...
Association of Baseline and Subsequent Cardiovascular Health Metrics to Risk for Incident Cancers
Matthew Stenger
In an analysis from the French GAZEL study reported in JACC: CardioOncology, Thomas Van Sloten, MD, PhD, of the Université Paris Cité, Institut National de la Santé et de la Recherche Médicale, Paris, and colleagues found that better cardiovascular health (CVH) scores at baseline and improvement in ...
Racial/Ethnic Disparities in All-Cause and Cardiovascular Mortality Among U.S. Patients With Cancer
Matthew Stenger
In an analysis reported in JACC: CardioOncology, Cenjing Zhu, MPhil, of the Department of Chronic Disease Epidemiology, Yale University, and colleagues found that Black patients with cancer in the United States were at increased risk of all-cause mortality and cardiovascular (CVD) mortality compared...
Rucaparib vs Physician’s Choice of Single-Agent Therapy in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Matthew Stenger
As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, of Gustave Roussy Institute, Paris-Saclay University, and colleagues, the phase III TRITON3 trial has shown significantly improved progression-free survival with rucaparib vs physician-selected single-agent therapy in the e...
Adjuvant Accelerated Partial-Breast Irradiation vs Whole-Breast Irradiation in Early Breast Cancer: 10 Year Outcomes of Phase III Study
Matthew Stenger
As reported in The Lancet Oncology by Vratislav Strnad, MD, PhD, of University Hospital Erlangen and Comprehensive Cancer Center Erlangen, Germany, and colleagues, 10-year outcomes in a phase III GEC-ESTRO (Groupe Européen de Curiethérapie and European Society for Radiotherapy and Oncology) trial ...
Zanubrutinib Improves Progression-Free Survival vs Ibrutinib in Relapsed or Refractory CLL or SLL
Matthew Stenger
As reported in The New England Journal of Medicine by Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute and Harvard University, and colleagues, the phase III ALPINE trial has shown significantly better progression-free survival with zanubrutinib, a Bruton’s tyrosine kinase (BTK) inhibito...
Mirvetuximab Soravtansine Active in Platinum-Resistant Ovarian Cancer With High FRα Expression
Matthew Stenger
As reported in the Journal of Clinical Oncology by Ursula A. Matulonis, MD, of the Dana-Farber Cancer Institute, and colleagues, the phase II SORAYA study has shown activity of mirvetuximab soravtansine-gynx, an antibody-drug conjugate targeting folate receptor α (FRα), in women with platinum-resist...
KRYSTAL-1 Confirms Activity of Adagrasib in KRAS G12C–Mutated Metastatic Colorectal Cancer and Highlights Need for Randomized Controlled Trials
Marwan Fakih, MD
KRAS G12C–mutated colorectal cancer represents 3% to 4% of metastatic colorectal cancers. Like other KRAS-mutated metastatic colorectal cancers, this group of patients represents a patient population with an unmet need, with limited options beyond two lines of therapy. In contrast to other KRAS muta...
Significant Benefit With Addition of Daratumumab to Bortezomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma
Matthew Stenger
As reported in the Journal of Clinical Oncology by Pieter Sonneveld, MD, PhD, of Erasmus MC Cancer Institute, Rotterdam, the Netherlands, and colleagues, the final overall survival analysis of the phase III CASTOR trial has shown a significant benefit of the addition of daratumumab to bortezomib/dex...
Adagrasib With or Without Cetuximab in Previously Treated Patients With Metastatic Colorectal Cancer and a KRAS G12C Mutation
Matthew Stenger
In a phase I/II trial (KRYSTAL-1) reported in The New England Journal of Medicine, Rona Yaeger, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues found that the KRAS G12C inhibitor adagrasib showed activity alone and in combination with cetuximab in heavily pretreated patients ...
Cardiovascular Events Before and After Initiation of Immune Checkpoint Inhibitor Therapy for Cancer
Matthew Stenger
In a study reported in JACC: CardioOncology, Lavanya Kondapalli, MD, of the University of Colorado School of Medicine, Aurora, and colleagues found that cardiovascular events common in the general population were observed both prior to and after the initiation of immune checkpoint inhibitor therapy ...
Risks of Cardiovascular and Immune-Related Adverse Events in Immune Checkpoint Inhibitor Therapy
Matthew Stenger
In a single academic hospital network retrospective case-control study reported in JACC:CardioOncology, Charlotte Lee, MD, of Columbia University Irving Medical Center, New York, along with senior author Tomas Neilan, MD, MPH, of Massachusetts General Hospital and colleagues found that patients with...
Study Explores the Addition of First-Line Atezolizumab in BRAF V600–Mutant Advanced Melanoma
Matthew Stenger
As reported in The Lancet Oncology by Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, and colleagues, the second interim overall survival analysis of the phase III IMspire150 trial has shown a numeric but statist...
Addition of Neoadjuvant Nivolumab to Chemotherapy Improves Complete Pathologic Response Rate and Event-Free Survival in Resectable NSCLC
Matthew Stenger
As reported in The New England Journal of Medicine by Patrick M. Forde, MB, BCh, of Johns Hopkins Kimmel Cancer Center, and colleagues, the phase III CheckMate 816 trial has shown improved pathologic complete response rate and event-free survival with the addition of nivolumab to platinum-based ch...
Novel Selective Estrogen Receptor Degraders in Advanced Breast Cancer: Use of Elacestrant in the Phase III EMERALD Trial
Melissa McShane, MD, and Lori J. Goldstein, MD, FASCO
Endocrine therapy is the foundation of first-line therapy in most patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Many of these patients respond to endocrine therapy but eventually become resistant to it through both intrinsic and acquired resistance mechanisms. This...
Lisocabtagene Maraleucel Improves Event-Free Survival in Second-Line Treatment of Relapsed or Refractory LBCL
Matthew Stenger
As reported in The Lancet by Manali Kamdar, MD, of the University of Colorado Cancer Center, Aurora, and colleagues, an interim analysis of the phase III TRANSFORM trial has shown significantly improved event-free survival with second-line lisocabtagene maraleucel vs standard-of-care salvage immunoc...
Increased Mortality From Comorbid Cancer and Cardiovascular Disease Associated With Increased Social Vulnerability
Matthew Stenger
In a U.S.-based cross-sectional study reported in JACC: CardioOncology, Sarju Ganatra, MD, of Lahey Hospital & Medical Center, Burlington, Massachusetts, and colleagues found that mortality from comorbid cancer and cardiovascular disease (CVD) was significantly higher in counties with higher v...
Elacestrant Improves Progression-Free Survival vs Standard Endocrine Therapy in Previously Treated Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
Matthew Stenger
As reported in the Journal of Clinical Oncology by François-Clément Bidard, MD, PhD, of the Institut Curie, Paris and Saint Cloud, and colleagues, the phase III EMERALD trial has shown prolonged progression-free survival with the oral selective estrogen receptor degrader elacestrant vs standard endo...
Axicabtagene Ciloleucel Improves Event-Free Survival vs Standard Care in Second-Line Treatment for Large B-Cell Lymphoma
Matthew Stenger
As reported in The New England Journal of Medicine by Frederick L. Locke, MD, of the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, Florida, and colleagues, the phase III ZUMA-7 trial in large B-cell lymphoma has shown improved event-free s...
T-DXd Improves Progression-Free Survival vs T-DM1 in Metastatic HER2-Positive Breast Cancer
Matthew Stenger
As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, of the International Breast Cancer Center, Barcelona, and colleagues, the phase III DESTINY-Breast03 trial has shown significantly prolonged progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs ado-tra...
Addition of Pembrolizumab to Chemotherapy Improves Event-Free Survival in Triple-Negative Breast Cancer
Matthew Stenger
As reported in The New England Journal of Medicine by Peter Schmid, MD, PhD, of Barts Cancer Institute, Queen Mary University of London, and colleagues, a preplanned interim analysis of the phase III KEYNOTE-522 trial has shown improved event-free survival with the addition of pembrolizumab to neoad...
Cabozantinib Prolongs Progression-Free Survival in Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer
Matthew Stenger
As reported in The Lancet Oncology by Marcia S. Brose, MD, Abramson Cancer Center, University of Pennsylvania, and colleagues, the phase III COSMIC-311 trial has shown that cabozantinib produced a numerically higher objective response rate and significantly prolonged progression-free survival vs pla...
Cardiovascular Mortality and Cancer Mortality Over Time Among Cancer Survivors
Matthew Stenger
In an English retrospective cohort study reported in JACC: Cardio-Oncology, Helen Strongman, PhD, of the Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, and colleagues found that cardiovascular mortality ultimately exceeded mortality from common p...
ASCO Guideline Update Supports New Second- and Third-Line Treatments for HER2-Positive Breast Cancer
Emily A. Kuhl, PhD
ASCO has issued a new practice guideline update on the use of systemic therapy for HER2-positive breast cancer, just 4 years after the previous practice guideline update was released in 2018.1,2 This latest update reviews results from multiple clinical trials published between 2016 and 2021 that cou...
Changing the Natural History of ER-Positive, HER2-Negative Breast Cancer With the Introduction of CDK4/6 Inhibition
Richard S. Finn, MD
It has been 14 years since a collaboration between the University of California, Los Angeles (UCLA) and Pfizer identified a unique role for cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in estrogen receptor (ER)-positive human cell line models and demonstrated that these agents act synergistically...
Time-Restricted Eating Intervention Reduces Cardiovascular Risk in Older Breast Cancer Survivors
Matthew Stenger
In a Canadian single-institution feasibility study reported in JACC: CardioOncology, Amy A. Kirkham, PhD, of the University of Toronto, and colleagues found that a time-restricted eating intervention reduced cardiovascular risk among older breast cancer survivors with risk factors for cardiovascular...
Addition of Ribociclib to Letrozole Improves Survival in Women With HR-Positive, HER2-Negative Advanced Breast Cancer
Matthew Stenger
As reported in The New England Journal of Medicine by Gabriel N. Hortobagyi, MD, of the Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, and colleagues, the protocol-specified final overall survival analysis of the phase III MONALEESA-2 trial has shown a significant benef...
ARIEL4 Trial: Rucaparib Improves Progression-Free Survival vs Chemotherapy in Relapsed Ovarian Cancer With BRCA1/2 Mutations
Matthew Stenger
As reported in The Lancet Oncology by Rebecca Kristeleit, MD, of Guy’s and St. Thomas’ NHS Foundation Trust, and colleagues, the phase III ARIEL4 trial has shown a statistically significant improvement in progression-free survival with rucaparib vs chemotherapy in relapsed ovarian cancer with delete...
Cancer Death Rates Among Black People Declined Over Time but Remain Higher Than Other Racial and Ethnic Groups
The ASCO Post Staff
From 1999 to 2019, rates of cancer deaths declined steadily among Black people in the United States. Nevertheless, in 2019, Black people still had considerably higher rates of cancer death than people in other racial and ethnic groups, a large epidemiologic study has found. The study was led by rese...
Addition of Anti–LAG-3 Antibody Relatlimab to Nivolumab Improves Progression-Free Survival in Previously Untreated Advanced Melanoma
Matthew Stenger
In a phase II/III trial (RELATIVITY-047) reported in The New England Journal of Medicine, Hussein A. Tawbi, MD, PhD, of The University of Texas MD Anderson Cancer Center, and colleagues found that the addition of relatlimab, a lymphocyte-activation gene 3 (LAG-3)–blocking antibody, to nivolumab sign...
Cemiplimab-rwlc Improves Overall Survival vs Chemotherapy in Recurrent Cervical Cancer After First-Line Platinum-Based Chemotherapy
Matthew Stenger
As reported in The New England Journal of Medicine by Krishnansu S. Tewari, MD, of the Division of Gynecologic Oncology, University of California, Irvine, and colleagues, the phase III EMPOWER-Cervical1/GOG-3016/ENGOT-cx9 trial has shown improved overall survival with cemiplimab-rwlc vs investigato...
T-DXd Improves Progression-Free Survival vs T-DM1 in Metastatic HER2-Positive Breast Cancer
Matthew Stenger
As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, of the International Breast Cancer Center, Barcelona, and colleagues, the phase III DESTINY-Breast03 trial has shown significantly prolonged progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs ado-tra...
DESTINY-Lung01: T-DXd Shows Durable Activity in Previously Treated Metastatic HER2-Mutant NSCLC
Matthew Stenger
In a phase II trial (DESTINY-Lung01) reported in The New England Journal of Medicine, Bob T. Li, MD, PhD, MPH, of the Thoracic Oncology and Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York, and colleagues found that fam-trastuzumab deruxtecan-nxki (T-DXd) showed durab...
5-Year Survival Outcomes With Consolidation Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC
Matthew Stenger
As reported in the Journal of Clinical Oncology by David R. Spigel, MD, of Sarah Cannon Research Institute/Tennessee Oncology, and colleagues, long-term follow-up of the phase III PACIFIC trial has shown maintained progression-free and overall survival benefits with consolidation durvalumab (a PD-L1...
Overall Survival Benefit With Nivolumab Plus Chemotherapy or Ipilimumab vs Chemotherapy Alone in Esophageal Squamous Cell Carcinoma
Matthew Stenger
As reported in The New England Journal of Medicine by Yuichiro Doki, MD, of Osaka University Graduate School of Medicine, Japan, and colleagues, the phase III CheckMate 648 trial has shown improved overall survival with nivolumab combined with chemotherapy or ipilimumab vs chemotherapy alone in pati...
Maintenance Daratumumab Prolongs Progression-Free Survival in Newly Diagnosed Multiple Myeloma
Matthew Stenger
As reported in The Lancet Oncology by Philippe Moreau, MD, of the University Hospital Hôtel-Dieu, Nantes, and colleagues, an interim analysis of part 2 of the phase III CASSIOPEIA trial has showed significantly prolonged progression-free survival with maintenance daratumumab vs observation following...
Subcutaneous Daratumumab Added to Pomalidomide Plus Dexamethasone Improves Progression-Free Survival in Multiple Myeloma
Matthew Stenger
As reported in The Lancet Oncology by Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, and colleagues, the phase III APOLLO trial has shown significantly improved progression-free survival with the addition of subcutaneous (SC) daratumumab to oral pomalidomide/dexam...
Dual PI3Kδ/CK1ε Inhibitor Umbralisib in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
Matthew Stenger
As reported in the Journal of Clinical Oncology by Nathan H. Fowler, MD, of The University of Texas MD Anderson Cancer Center, and colleagues, a phase IIb trial (UNITY-NHL) has shown that the dual PI3Kδ/casein kinase (CK)1ε inhibitor umbralisib produced durable responses in patients with relapsed or...
Addition of Copanlisib to Rituximab Improves Progression-Free Survival in Relapsed Indolent Non-Hodgkin Lymphoma
Matthew Stenger
As reported in The Lancet Oncology by Matthew J. Matasar, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, the phase III CHRONOS-3 trial has shown that the addition of the pan-class I PI3K inhibitor copanlisib to rituximab significantly improved progression-free survival vs rituximab...
Incidental Findings on Low-Dose CT Lung Cancer Screening in the NLST and Risk of Respiratory Disease Mortality
Matthew Senger
In an analysis of data from the National Lung Screening Trial (NLST) reported in Chest, Paul F. Pinsky, PhD, of the Division of Cancer Prevention, National Cancer Institute, and colleagues found that incidental respiratory disease–related findings on low-dose computed tomography (CT) screening wer...
Association of Lifestyle and Cardiovascular Risk Factors With Hospitalization for Heart Failure Subtypes in Breast Cancer Survivors
Matthew Stenger
In an analysis from the Women’s Health Initiative reported in JACC: CardioOncology, Kerryn W. Reding, PhD, MPH, RN, of the University of Washington at Seattle, and colleagues, identified the incidence of hospitalization for heart failure among postmenopausal breast cancer survivors. They reported th...
